Price$4.56+0.06 (+1.33%)
01:30 PM07:45 PM
News · 26 weeks30-17%
2025-12-072026-05-31
Mix2390d
- SEC Filings9(39%)
- Insider6(26%)
- Other4(17%)
- Leadership2(9%)
- Analyst1(4%)
- Dividends1(4%)
Latest news
25 items- INSIDERChief Technology Officer Sripad Umesh was granted 75,000 shares (SEC Form 4)4 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sripad Umesh3 - LifeMD, Inc. (0000948320) (Issuer)
- PRLifeMD Appoints Umesh Sripad as Chief Technology OfficerNEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading direct-to-patient telehealth company, today announced the appointment of Umesh Sripad as Chief Technology Officer (CTO), effective immediately. In this role, Mr. Sripad will lead LifeMD's technology strategy, platform transformation, AI enablement, cybersecurity, data infrastructure, and enterprise scalability initiatives as the company continues its rapid expansion. "Over the past five years, LifeMD has grown from a small men's virtual pharmacy platform into a 50-state virtual primary, specialty care, and pharmacy platform that serves nearly 350,000 patients," said Justin Schreiber, Chairman & Chief Executi
- PRLifeMD to Participate in Upcoming Investor ConferencesNEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading platform for virtual primary care services, today announced that management will be participating in two upcoming investor conferences. LD Micro Invitational XVI Conference, May 17 - 19, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles. Management will deliver a company presentation on Tuesday, May 19th at 9:00 a.m. Pacific time and will be available for one-on-one meetings. Investors can register for the conference here.B. Riley Securities 26th Annual Investor Conference, May 20 - 21, 2026, in Marina del Rey, Calif. Management will be holding one-on-one meetings on Wednesday, May 20th. Investors can re
- INSIDERChief Financial Officer Kavthekar Atul was granted 337,500 shares (SEC Form 4)4 - LifeMD, Inc. (0000948320) (Issuer)
- SECSEC Form 10-Q filed by LifeMD Inc.10-Q - LifeMD, Inc. (0000948320) (Filer)
- SECLifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LifeMD, Inc. (0000948320) (Filer)
- SECSEC Form DEFA14A filed by LifeMD Inc.DEFA14A - LifeMD, Inc. (0000948320) (Filer)
- SECSEC Form DEFA14A filed by LifeMD Inc.DEFA14A - LifeMD, Inc. (0000948320) (Filer)
- SECSEC Form DEF 14A filed by LifeMD Inc.DEF 14A - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD to Report First Quarter 2026 Financial Results on May 6NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on May 6, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Wednesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:877-270-2148International Dial-In:412-902-6510Conference ID:LifeMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and
- PRLifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight ManagementNEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Foundayo is available to eligible LifeMD patients through the Company's integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage. Patients with eligible commer
- INSIDERSEC Form 4 filed by Pisano Christopher A4 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pisano Christopher A3 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kavthekar Atul3 - LifeMD, Inc. (0000948320) (Issuer)
- SECSEC Form S-8 filed by LifeMD Inc.S-8 - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription ProgramNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable for
- PRLifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea
- SECLifeMD Inc. filed SEC Form 8-K: Leadership Update8-K - LifeMD, Inc. (0000948320) (Filer)
- ANALYSTLifeMD upgraded by Mizuho with a new price targetMizuho upgraded LifeMD from Neutral to Outperform and set a new price target of $8.00
- PRLifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership TeamNEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. "We are thrilled to welcome Atul to LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD. "He is a versatile financial leader who has spent nearly three decades helping healthcare and technology companies scale, and h
- SECSEC Form 10-K filed by LifeMD Inc.10-K - LifeMD, Inc. (0000948320) (Filer)
- SECLifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD to Participate in Two Investor Conferences During MarchNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. Eastern time and a virtual panel titled "The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals" at 12:00 p.m. Eastern time. In addition, man
- PRLifeMD to Report Fourth Quarter 2025 Financial Results on March 9NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser
LFMD FAQ
6 questionsWhat does LifeMD Inc. do?
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a medical device for male and female hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; Nava MD, a female-oriented tele-dermatology and skincare brand that would offer virtual medical treatment from dermatologists and other...Where does LFMD stock trade?
LifeMD Inc. (LFMD) is listed on NASDAQ.What sector and industry is LFMD in?
LifeMD Inc. operates in the Health Care sector, Medical/Nursing Services industry.What are analysts saying about LFMD?
LifeMD Inc. has had 8 recent analyst actions on file. The most recent action was from Mizuho: Outperform with a $800.00 price target on 2026-03-16. Recent price targets range from $700.00 to $1800.00.What companies are similar to LFMD?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), AMED (Amedisys Inc), LHCG (LHC Group). Compare LFMD side-by-side with any of them on Quantisnow.How can I track LFMD on Quantisnow?
Quantisnow aggregates LifeMD Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFMD to receive live email and push alerts on every new disclosure.